Karuna Therapeutics KRTX 深 沪
等待开盘 04-02 09:30:00 美东时间
329.83
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 329.83
- 总市值 125.99亿
- 52周最高 329.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 158.375
- 委 比 0.00%
- 总股本 3819.93万
- 历史最高 329.99
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.24
- 每 手 1
- 风险率 65.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Kyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D., to its Board of Directors. Mr. Emany brings extensive financial and strategic leadership experience, while Dr. Miller adds expertise in clinical development and product approval. Their加入 strengthens the company as it advances toward commercialization and long-term success in autoimmune CAR T therapies.
02-24 13:00
聚焦中概 | 热门中概股走势分化！再鼎医药大涨超6%；霸王茶姬跌近3%
热门中概股走势分化！再鼎医药大涨超6%，抗精神分裂症新药国内获批上市；拼多多、贝壳涨超1%；霸王茶姬跌近3%，金山云、网易、哔哩哔哩跌超1%>>
2025-12-24 23:44
Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT Study
Karuna Therapeutics, Inc. (($KRTX)) announced an update on their ongoing clinic...
2025-08-16 00:24
今年CNS领域最大融资诞生
（来源：动脉新医药） 当地时间2025年7月28日，中枢神经系统疾病治疗方法开发商MapLight Therapeutics宣布完成3.725亿美元的超额认购...
2025-07-30 16:42
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
July 9 (Reuters) - Merck MRK.N is acquiring UK-based Verona Pharma VRNA.O for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda....
2025-07-10 01:28
Karuna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT Study
Karuna Therapeutics, Inc. (($KRTX)) announced an update on their ongoing clinic...
2025-07-03 00:14
BUZZ-Incyte appoints Bill Meury as CEO, shares rise
** Shares of drugmaker Incyte INCY.O rise as much as 4.4% to a 4-month high of $71.50 ** INCY says it has appointed Bill Meury as CEO, effective immediately ** Meury replaces Hervé Hoppenot, who has b...
2025-06-27 00:50
BUZZ-Bristol Myers drops as schizophrenia drug fails in late-stage trial as add-on treatment
** Shares of drugmaker Bristol Myers Squibb BMY.N fall 6.8% to $46.41 after the bell ** BMY says its drug Cobenfy failed to show to statistically significant difference compared to placebo in a late-s...
2025-04-23 04:34
UPDATE 3-Bristol Myers' Cobenfy fails in key study as add-on treatment for schizophrenia
Adds analyst comment in paragraph 6 By Sriparna Roy April 22 (Reuters) - Bristol Myers Squibb BMY.N said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly w...
2025-04-23 04:29
再鼎医药抗精分药KarXT申报上市
1月17日，再鼎医药宣布KarXT（呫诺美林+曲司氯铵）用于治疗成人精神分裂症的新药上市申请（NDA）已获国家药品监督管理局（NMPA）受理。 Kar...
2025-01-18 08:08
